KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.

Jun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, Eun-Gyoung Hong, Hae Jin Kim, Chang Beom Lee, Ho Chan Cho, Jong Chul Won, Hun-Sung Kim, Eui-Hyun Kim, Gwanpyo Koh, Kwang Hyun Ahn, Kyong Soo Park

Diabetes Metab J 50(2) 320-330

PMID41151541
PMCIDPMC12996957
DOI10.4093/dmj.2024.0696
发表日期2025-10-28
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 other;Fig. 2.:AI 判定为 other;Fig. 3.:AI 判定为 multi panel km;captionless-figure:AI 判定为 other。
摘要

摘要

BACKGRUOUND: This study investigated the efficacy and safety of pioglitazone 30 mg/day add-on to inadequately controlled type 2 diabetes mellitus (T2DM) patients with treatment of dapagliflozin and metformin. METHODS: In this multicenter (34 sites), double-blind, randomized, phase 3 study, patients with T2DM with an inadequately controlled glycosylated hemoglobin (HbA1c) over 7.0% to treatment with dapagliflozin (10 mg/day) and metformin (≥1,000 mg/day) were randomized to receive additional pioglitazone 30 mg/day (n=124) or placebo (n=122) for 24 weeks. The primary outcome was the mean change of HbA1c from baseline to 24 weeks treatment. The efficacy and safety were evaluated with open label extension period, switching placebo to pioglitazone 30 mg/day at 48 weeks (ClinicalTrials.gov identifier: NCT05296044). RESULTS: The HbA1c after 24 weeks treatment reduced from 7.8%±0.8% to 7.0%±0.6% (P<0.0001). The proportions of patients who achieved HbA1c less than 7.0% at 24 weeks were significantly higher in pioglitazone add-on group (51.61% in pioglitazone vs. 22.95% in placebo, P<0.0001), or less than 6.5% at 24 weeks (21.77% in pioglitazone vs. 2.46% in placebo, P<0.0001). Body weight gain was 2.0 kg at 24 weeks with pioglitazone 30 mg/day and -0.6 kg at 24 weeks with placebo. CONCLUSION: Addition of pioglitazone 30 mg/day to T2DM patients who did not reach the target HbA1c (≤7%) with treatment of dapagliflozin 10 mg/day and metformin over 1,000 mg/day showed effective glucose lowering efficacy without significant hypoglycemia and good tolerability with low prevalence of edema in spite of modest weight gain.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Primary outcome: Least square (LS) mean change of glycosylated hemoglobin (HbA1c) from baseline to 24 weeks treatment (A). Changes of HbA1c in primary and extension period (B) and changes in fasting plasma glucose (FPG) in primary and extension period (C) for 24 weeks after additional of pioglitazone 30 mg/day to patients with uncontrolled type 2 diabetes mellitus treated with dapagliflozin and metformin. Data are mean±standard error of mean. SE, standard error. Significant change from the baseline a P <0.001, b P <0.0001; Significant difference between the groups c P <0.0001.
非 KM Figure
Fig. 2.Fig. 2. Least square (LS) mean change in (A) fasting plasma glucose (FPG), (B) fasting insulin, and (C) homeostatic model assessment for insulin resistance (HOMA-IR), and (D) homeostatic model assessment of β-cell function (HOMA-β) from baseline to 24 weeks treatment. SE, standard error. Significant change from the baseline a P <0.0001; Significant difference between the groups b P <0.05, c P <0.001, d P <0.0001.
非 KM Figure
Fig. 3.Fig. 3. (A) Participants who achieved target glycosylated hemoglobin (HbA1c) below 7.0% and 6.5% after treatment of add-on pioglitazone 30 mg/day or placebo to patients with uncontrolled type 2 diabetes mellitus treated with dapagliflozin and metformin at 24 weeks. (B) Changes of body weight at 12, 24 weeks after treatment of pioglitazone 30 mg/day add-on or placebo to patients with uncontrolled type 2 diabetes mellitus treated with dapagliflozin and metformin. SE, standard error. Significant change from the baseline a P <0.05, b P <0.0001; Significant difference between the groups c P <0.0001.
非 KM Figure
captionless-figurecaptionless-figure
非 KM Figure